Top

Breast Cancer Research and Treatment

Published in:

13-02-2023 | Fertility | Clinical trial

Comparison of goserelin and leuprorelin for ovarian protection during chemotherapy in young patients with breast cancer

Authors: Sung Eun Kim, Won-Ji Kim, DooSeok Choi, Dong-Yun Lee

Published in: Breast Cancer Research and Treatment | Issue 2/2023

Abstract

Purpose

Although different gonadotropin-releasing hormone (GnRH) agonists may have different effects, their effect of ovarian protection during chemotherapy for breast cancer has not been compared. This study aimed to compare the effects of goserelin and leuprorelin for ovarian protection during chemotherapy in young patients with breast cancer.

Methods

This prospective study analyzed 193 patients with breast cancer aged ≤ 40 years who had regular menstruation and serum anti-Müllerian hormone (AMH) levels ≥ 1 ng/mL before treatment. Patients received either goserelin or leuprorelin for ovarian protection during doxorubicin/cyclophosphamide-based chemotherapy. Resumption of menstruation and changes in serum levels of AMH were compared between the two groups at 12 months after completion of chemotherapy.

Results

The mean age and the pretreatment serum AMH level were 33.2 years and 4.4 ng/mL in goserelin group and 34.2 years and 4.0 ng/mL in leuprorelin group. The proportion of patients who resumed menstruation was not different between the goserelin (94.4%) and leuprorelin (95.3%) groups at 12 months after chemotherapy completion. Serum AMH levels decreased significantly in both the goserelin (from 4.4 to 1.2 ng/mL) and leuprorelin (from 4.0 to 1.2 ng/mL) groups, with no statistical significance. In addition, no difference was found in the proportion of patients with serum AMH levels ≥ 1 ng/mL between the goserelin (49.5%) and leuprorelin (44.2%) groups at 12 months after chemotherapy.

Conclusion

Goserelin and leuprorelin were comparable in terms of ovarian protection during doxorubicin/cyclophosphamide-based chemotherapy in young patients with breast cancer.

Assi HA, Khoury KE, Dbouk H, Khalil LE, Mouhieddine TH, El Saghir NS (2013) Epidemiology and prognosis of breast cancer in young women. J Thorac Dis 5(Suppl 1):S2-8. https://doi.org/10.3978/j.issn.2072-1439.2013.05.24CrossRefPubMedPubMedCentral

Anders CK, Johnson R, Litton J, Phillips M, Bleyer A (2009) Breast cancer before age 40 years. Semin Oncol 36:237–249. https://doi.org/10.1053/j.seminoncol.2009.03.001CrossRefPubMedPubMedCentral

Cardoso F, Loibl S, Pagani O, Graziottin A, Panizza P, Martincich L, Gentilini O, Peccatori F, Fourquet A, Delaloge S, Marotti L, Penault-Llorca F, Kotti-Kitromilidou AM, Rodger A, Harbeck N (2012) The European Society of Breast Cancer Specialists recommendations for the management of young women with breast cancer. Eur J Cancer 48:3355–3377. https://doi.org/10.1016/j.ejca.2012.10.004CrossRefPubMed

Chen HL, Zhou MQ, Tian W, Meng KX, He HF (2016) Effect of age on breast cancer patient prognoses: a population-based study using the SEER 18 database. PLoS One 11:e0165409. https://doi.org/10.1371/journal.pone.0165409CrossRefPubMedPubMedCentral

Anders CK, Hsu DS, Broadwater G, Acharya CR, Foekens JA, Zhang Y, Wang Y, Marcom PK, Marks JR, Febbo PG, Nevins JR, Potti A, Blackwell KL (2008) Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol 26:3324–3330. https://doi.org/10.1200/jco.2007.14.2471CrossRefPubMed

Oktem O, Oktay K (2007) Quantitative assessment of the impact of chemotherapy on ovarian follicle reserve and stromal function. Cancer 110:2222–2229. https://doi.org/10.1002/cncr.23071CrossRefPubMed

Lee SJ, Schover LR, Partridge AH, Patrizio P, Wallace WH, Hagerty K, Beck LN, Brennan LV, Oktay K (2006) American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 24:2917–2931. https://doi.org/10.1200/jco.2006.06.5888CrossRefPubMed

Oktay K, Harvey BE, Partridge AH, Quinn GP, Reinecke J, Taylor HS, Wallace WH, Wang ET, Loren AW (2018) Fertility preservation in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol 36:1994–2001. https://doi.org/10.1200/jco.2018.78.1914CrossRefPubMed

Paluch-Shimon S, Cardoso F, Partridge AH, Abulkhair O, Azim HA Jr, Bianchi-Micheli G, Cardoso MJ, Curigliano G, Gelmon KA, Harbeck N, Merschdorf J, Poortmans P, Pruneri G, Senkus E, Spanic T, Stearns V, Wengström Y, Peccatori F, Pagani O (2020) ESO-ESMO 4th international consensus guidelines for breast cancer in young women (BCY4). Ann Oncol 31:674–696. https://doi.org/10.1016/j.annonc.2020.03.284CrossRefPubMed

10.

Practice Committee of the American Society for Reproductive Medicine (2019) Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion. Fertil Steril 112:1022–1033. https://doi.org/10.1016/j.fertnstert.2019.09.013

11.

Lambertini M, Boni L, Michelotti A, Gamucci T, Scotto T, Gori S, Giordano M, Garrone O, Levaggi A, Poggio F, Giraudi S, Bighin C, Vecchio C, Sertoli MR, Pronzato P, Del Mastro L (2015) Ovarian suppression with triptorelin during adjuvant breast cancer chemotherapy and long-term ovarian function, pregnancies, and disease-free survival: a randomized clinical trial. JAMA 314:2632–2640. https://doi.org/10.1001/jama.2015.17291CrossRefPubMed

12.

Moore HCF, Unger JM, Phillips KA, Boyle F, Hitre E, Moseley A, Porter DJ, Francis PA, Goldstein LJ, Gomez HL, Vallejos CS, Partridge AH, Dakhil SR, Garcia AA, Gralow JR, Lombard JM, Forbes JF, Martino S, Barlow WE, Fabian CJ, Minasian LM, Meyskens FL, Gelber RD, Hortobagyi GN, Albain KS (2019) Final analysis of the prevention of early menopause study (POEMS)/SWOG intergroup S0230. J Natl Cancer Inst 111:210–213. https://doi.org/10.1093/jnci/djy185CrossRefPubMed

13.

Leonard RCF, Adamson DJA, Bertelli G, Mansi J, Yellowlees A, Dunlop J, Thomas GA, Coleman RE, Anderson RA (2017) GnRH agonist for protection against ovarian toxicity during chemotherapy for early breast cancer: the Anglo Celtic Group OPTION trial. Ann Oncol 28:1811–1816. https://doi.org/10.1093/annonc/mdx184CrossRefPubMed

14.

Lambertini M, Moore HCF, Leonard RCF, Loibl S, Munster P, Bruzzone M, Boni L, Unger JM, Anderson RA, Mehta K, Minton S, Poggio F, Albain KS, Adamson DJA, Gerber B, Cripps A, Bertelli G, Seiler S, Ceppi M, Partridge AH, Del Mastro L (2018) Gonadotropin-releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in premenopausal patients with early breast cancer: a systematic review and meta-analysis of individual patient-level data. J Clin Oncol 36:1981–1990. https://doi.org/10.1200/jco.2018.78.0858CrossRefPubMedPubMedCentral

15.

Chen H, Xiao L, Li J, Cui L, Huang W (2019) Adjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in premenopausal women. Cochrane Database Syst Rev 3:CD008018. https://doi.org/10.1002/14651858.CD008018.pub3CrossRefPubMed

16.

Maisano R, Caristi N, Mare M, Bottari M, Adamo V, Mafodda A, Calogero MG, Caruso M, Nardi M (2008) Protective effect of leuprolide on ovarian function in young women treated with adjuvant chemotherapy for early breast cancer: a multicenter phase II study. J Chemother 20:740–743. https://doi.org/10.1179/joc.2008.20.6.740CrossRefPubMed

17.

Song G, Gao H, Yuan Z (2013) Effect of leuprolide acetate on ovarian function after cyclophosphamide-doxorubicin-based chemotherapy in premenopausal patients with breast cancer: results from a phase II randomized trial. Med Oncol 30:667. https://doi.org/10.1007/s12032-013-0667-8CrossRefPubMed

18.

Robertson JF, Blamey RW (2003) The use of gonadotrophin-releasing hormone (GnRH) agonists in early and advanced breast cancer in pre- and perimenopausal women. Eur J Cancer 39:861–869. https://doi.org/10.1016/s0959-8049(02)00810-9CrossRefPubMed

19.

Lee DY, Park YH, Lee JE, Choi D (2018) Prediction of ovarian function recovery in young breast cancer patients after protection with gonadotropin-releasing hormone agonist during chemotherapy. Breast Cancer Res Treat 171:649–656. https://doi.org/10.1007/s10549-018-4863-2CrossRefPubMed

20.

Lee DY, Kim JY, Yu J, Kim SW (2020) Prediction of successful ovarian protection using gonadotropin-releasing hormone agonists during chemotherapy in young estrogen receptor-negative breast cancer patients. Front Oncol 10:863. https://doi.org/10.3389/fonc.2020.00863CrossRefPubMedPubMedCentral

21.

Lambertini M, Horicks F, Del Mastro L, Partridge AH, Demeestere I (2019) Ovarian protection with gonadotropin-releasing hormone agonists during chemotherapy in cancer patients: from biological evidence to clinical application. Cancer Treat Rev 72:65–77. https://doi.org/10.1016/j.ctrv.2018.11.006CrossRefPubMed

22.

Aydiner A, Kilic L, Yildiz I, Keskin S, Sen F, Kucucuk S, Karanlik H, Muslumanoglu M, Igci A (2013) Two different formulations with equivalent effect? Comparison of serum estradiol suppression with monthly goserelin and trimonthly leuprolide in breast cancer patients. Med Oncol 30:354. https://doi.org/10.1007/s12032-012-0354-1CrossRefPubMed

23.

Kim HJ, Lee JS, Park EH, Lim WS, Sei JY, Koh BS, Son BH, Ahn JH, Jeong KH, Kim SB, Ahn SH (2009) Short term results from GHRH analogue use in pre-menopausal breast cancer in Korea. Eur J Surg Oncol 35:936–941. https://doi.org/10.1016/j.ejso.2009.01.016CrossRefPubMed

24.

Dias Silva É, Ferreira U, Matheus W, Faria EF, Silva GD, Saito M, de Souza AA, Laranjo A Jr, Clark O, Magna LA, Castilho LN, Reis LO (2012) Goserelin versus leuprolide in the chemical castration of patients with prostate cancer. Int Urol Nephrol 44:1039–1044. https://doi.org/10.1007/s11255-012-0134-zCrossRefPubMed

25.

Moore HC, Unger JM, Phillips KA, Boyle F, Hitre E, Porter D, Francis PA, Goldstein LJ, Gomez HL, Vallejos CS, Partridge AH, Dakhil SR, Garcia AA, Gralow J, Lombard JM, Forbes JF, Martino S, Barlow WE, Fabian CJ, Minasian L, Meyskens FL Jr, Gelber RD, Hortobagyi GN, Albain KS (2015) Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med 372:923–932. https://doi.org/10.1056/NEJMoa1413204CrossRefPubMedPubMedCentral

26.

Badawy A, Elnashar A, El-Ashry M, Shahat M (2009) Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study. Fertil Steril 91:694–697. https://doi.org/10.1016/j.fertnstert.2007.12.044CrossRefPubMed

27.

de AndersonAmantBraatD’AngeloSousa LopesDemeestereDwek RAFDASM ChuvaIS, Frith L, Lambertini M, Maslin C, Moura-Ramos M, Nogueira D, Rodriguez-Wallberg K, Vermeulen N (2020) ESHRE guideline: female fertility preservation. Hum Reprod Open 2020:hoaa052. https://doi.org/10.1093/hropen/hoaa052CrossRef

28.

Behringer K, Wildt L, Mueller H, Mattle V, Ganitis P, van den Hoonaard B, Ott HW, Hofer S, Pluetschow A, Diehl V, Engert A, Borchmann P (2010) No protection of the ovarian follicle pool with the use of GnRH-analogues or oral contraceptives in young women treated with escalated BEACOPP for advanced-stage Hodgkin lymphoma. Final results of a phase II trial from the German Hodgkin Study Group. Ann Oncol 21:2052–2060. https://doi.org/10.1093/annonc/mdq066CrossRefPubMed

29.

Gerber B, von Minckwitz G, Stehle H, Reimer T, Felberbaum R, Maass N, Fischer D, Sommer HL, Conrad B, Ortmann O, Fehm T, Rezai M, Mehta K, Loibl S (2011) Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study. J Clin Oncol 29:2334–2341. https://doi.org/10.1200/jco.2010.32.5704CrossRefPubMed

30.

Elgindy EA, El-Haieg DO, Khorshid OM, Ismail EI, Abdelgawad M, Sallam HN, Abou-Setta AM (2013) Gonadatrophin suppression to prevent chemotherapy-induced ovarian damage: a randomized controlled trial. Obstet Gynecol 121:78–86. https://doi.org/10.1097/aog.0b013e31827374e2CrossRefPubMed

Title: Comparison of goserelin and leuprorelin for ovarian protection during chemotherapy in young patients with breast cancer
Authors: Sung Eun Kim
Won-Ji Kim
DooSeok Choi
Dong-Yun Lee
Publication date: 13-02-2023
Publisher: Springer US
Keywords: Fertility
Breast Cancer
Breast Cancer
Goserelin
GnRH Agonists
Leuprolide
Cytostatic Therapy
Published in: Breast Cancer Research and Treatment / Issue 2/2023
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-023-06877-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2023

Prognostic significance of pretreatment 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with T2N1 hormone receptor-positive, ERBB2-negative breast cancer who underwent adjuvant chemotherapy

Validation of a breast cancer risk prediction model based on the key risk factors: family history, mammographic density and polygenic risk

Chemotherapy refusal and subsequent survival in healthy older women with high genomic risk estrogen receptor-positive breast cancer

Outcomes for the first four lines of therapy in patients with HER2-positive advanced breast cancer: results from the SONABRE registry

Neighborhood and racial influences on triple negative breast cancer: evidence from Northeast Ohio

Contrast-enhanced mammography in the assessment of residual disease after neoadjuvant treatment

Keynote webinar | Spotlight on antibody–drug conjugates in cancer